JP2005533808A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533808A5
JP2005533808A5 JP2004515895A JP2004515895A JP2005533808A5 JP 2005533808 A5 JP2005533808 A5 JP 2005533808A5 JP 2004515895 A JP2004515895 A JP 2004515895A JP 2004515895 A JP2004515895 A JP 2004515895A JP 2005533808 A5 JP2005533808 A5 JP 2005533808A5
Authority
JP
Japan
Prior art keywords
substituted
ylamino
thiazol
pyridin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004515895A
Other languages
English (en)
Japanese (ja)
Other versions
JP4477492B2 (ja
JP2005533808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/019243 external-priority patent/WO2004001059A2/en
Publication of JP2005533808A publication Critical patent/JP2005533808A/ja
Publication of JP2005533808A5 publication Critical patent/JP2005533808A5/ja
Application granted granted Critical
Publication of JP4477492B2 publication Critical patent/JP4477492B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004515895A 2002-06-20 2003-06-18 キナーゼ類のヘテロ環阻害剤 Expired - Fee Related JP4477492B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39081302P 2002-06-20 2002-06-20
PCT/US2003/019243 WO2004001059A2 (en) 2002-06-20 2003-06-18 Heterocyclic inhibitors of kinases

Publications (3)

Publication Number Publication Date
JP2005533808A JP2005533808A (ja) 2005-11-10
JP2005533808A5 true JP2005533808A5 (cg-RX-API-DMAC7.html) 2006-03-02
JP4477492B2 JP4477492B2 (ja) 2010-06-09

Family

ID=30000629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004515895A Expired - Fee Related JP4477492B2 (ja) 2002-06-20 2003-06-18 キナーゼ類のヘテロ環阻害剤

Country Status (14)

Country Link
US (2) US7084160B2 (cg-RX-API-DMAC7.html)
EP (1) EP1513818B1 (cg-RX-API-DMAC7.html)
JP (1) JP4477492B2 (cg-RX-API-DMAC7.html)
AR (1) AR040272A1 (cg-RX-API-DMAC7.html)
AT (1) ATE455767T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003251559A1 (cg-RX-API-DMAC7.html)
DE (1) DE60331061D1 (cg-RX-API-DMAC7.html)
ES (1) ES2337246T3 (cg-RX-API-DMAC7.html)
IS (1) IS7599A (cg-RX-API-DMAC7.html)
NO (1) NO330043B1 (cg-RX-API-DMAC7.html)
PE (1) PE20040581A1 (cg-RX-API-DMAC7.html)
PL (1) PL374272A1 (cg-RX-API-DMAC7.html)
TW (1) TW200401638A (cg-RX-API-DMAC7.html)
WO (1) WO2004001059A2 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
NZ537208A (en) * 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
ATE350383T1 (de) * 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2005004864A1 (en) * 2003-07-11 2005-01-20 Merck Patent Gmbh Benzimidazole derivatives as raf kinase inhibitors
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7449167B2 (en) * 2004-07-08 2008-11-11 Air Products And Chemicals, Inc. Catalyst and process for improving the adiabatic steam-reforming of natural gas
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
WO2006134989A1 (ja) * 2005-06-15 2006-12-21 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2007067257A2 (en) 2005-12-02 2007-06-14 Vanderbilt University Broad-emission nanocrystals and methods of making and using same
WO2007071422A2 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
WO2007071955A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Chemical compounds
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
DK2010168T3 (da) 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
EP2004614B1 (en) * 2006-04-13 2016-10-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
JP5244118B2 (ja) 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
EP2111402B1 (en) * 2007-01-05 2012-03-07 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
US8227470B2 (en) 2007-01-12 2012-07-24 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
CN101883777B (zh) 2007-10-01 2015-03-25 Isis制药公司 成纤维细胞生长因子受体4表达的反义调节
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20170349540A1 (en) * 2014-07-28 2017-12-07 The General Hospital Corporation Histone deacetylase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN116751195B (zh) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 联吡啶类化合物、其可药用的盐以及制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0841008A (ja) * 1994-07-29 1996-02-13 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU768751B2 (en) * 1998-06-18 2004-01-08 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) * 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
PL219736B1 (pl) * 2002-04-23 2015-07-31 Bristol Myers Squibb Co Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP5886411B2 (ja) 新規のピリミジン誘導体
JP2007530459A5 (cg-RX-API-DMAC7.html)
JP2010538076A5 (cg-RX-API-DMAC7.html)
ES2344484T3 (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38.
US20210261542A1 (en) Compounds which inhibit rna polymerase, compositions including such compounds, and their use
JP2007505877A5 (cg-RX-API-DMAC7.html)
KR970703333A (ko) 5-HT_1A 길항제로서의 피페라진 유도체(Piperazine derivatives as 5-HT_1A antagonists)
JP2012530765A5 (cg-RX-API-DMAC7.html)
CA2536954A1 (en) C-kit modulators and methods of use
JP2009529059A5 (cg-RX-API-DMAC7.html)
PT1533304E (pt) Derivado de amida
RU2008143232A (ru) Новый класс ингибиторов гистондеацетилаз
CA2720176A1 (en) Antiproliferative compounds and therapeutic uses thereof
CA3076667C (en) Phenylpyridine derivative and pharmaceutical composition comprising the same
JP2005532397A5 (cg-RX-API-DMAC7.html)
JP2009514899A5 (cg-RX-API-DMAC7.html)
CA2380986C (en) Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
CA2576065A1 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
JP2004522759A (ja) 抗血栓性化合物、その製法及び医薬組成物としての使用
DE102005005395A1 (de) Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
WO2004060281A2 (en) 2-aryl thiazole derivatives as kcnq modulators
US20020151534A1 (en) Antithrombotic compounds
JP4954895B2 (ja) 新規なヘテロアリールアセトアミド類
CA2528010A1 (en) 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
TH67633A (th) ตัวยับยั้งชนิดเฮเทอโรไซคลิกของไคเนส